Vyne Therapeutics Inc.
13F holders, Q2 2025 (June 30)At the end of Q2 2025, 44 institutions reported holding Vyne Therapeutics Inc. in their 13F filings, up 7 from Q1 2025. 14 opened new positions and 7 sold out. The largest holders were Cormorant Asset Management, LP ($2.3M), Citadel Advisors ($1.7M) and Acorn Capital Advisors, LLC ($1.2M). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Vyne Therapeutics Inc.
- CUSIP
- 92941V308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 14 | $4.6M |
| Exits | 7 | $3.0M |
All 13F filers, Q1 2025 → Q2 2025: 3,328,525 shares bought and 2,390,046 shares sold, net +938,479 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 44 holders
| Cormorant Asset Management, LP | 0.17% | New | 1,370,938 | $2.3M |
| Citadel Advisors | 0.00% | Reduce -5.5% | 1,040,070 | $1.7M |
| Acorn Capital Advisors, LLC | 0.79% | Reduce -6.3% | 736,572 | $1.2M |
| Adage Capital Partners Gp, L.L.C. | 0.00% | Add +87.2% | 644,134 | $1.1M |
| DAFNA Capital Management LLC | 0.29% | No change | 636,103 | $1.0M |
| Kennedy Capital Management LLC | 0.02% | New | 570,740 | $942K |
| Vanguard Group Inc. | 0.00% | Add +4.3% | 496,297 | $819K |
| Palo Alto Investors LP | 0.16% | No change | 445,434 | $735K |
| Patient Square Capital LP | 0.19% | Add +23.3% | 317,033 | $523K |
| Ikarian Capital, LLC | 0.16% | New | 290,000 | $479K |
| Exome Asset Management LLC | 0.28% | Reduce -54.9% | 208,970 | $345K |
| Schonfeld Strategic Advisors LLC | 0.00% | Add +90.6% | 161,951 | $267K |
| Geode Capital Management, LLC | 0.00% | Reduce -0.1% | 133,329 | $220K |
| Jane Street Group, LLC | 0.00% | New | 124,822 | $206K |
| Tetragon Partners GP Ltd | 0.05% | New | 115,384 | $190K |
| Boothbay Fund Management, LLC | 0.01% | New | 106,459 | $176K |
| Squarepoint Ops LLC | 0.00% | New | 78,474 | $129K |
| Bridgeway Capital Management, LLC | 0.00% | Add +48.1% | 76,958 | $127K |
| Prelude Capital Management, LLC | 0.01% | Reduce -54.4% | 64,584 | $107K |
| Susquehanna International Group, LLP | 0.00% | Add +0.1% | 57,814 | $95K |
| XTX Topco Ltd | 0.00% | Add +72.2% | 56,908 | $94K |
| Harvest Investment Services, LLC | 0.02% | New | 51,326 | $85K |
| BlackRock, Inc. | 0.00% | Reduce -46.2% | 44,405 | $73K |
| HRT Financial LP | 0.00% | Add +60.2% | 42,037 | $69K |
| Velan Capital Investment Management LP | 0.05% | New | 30,000 | $50K |
| Northern Trust Corp. | 0.00% | Reduce -3.6% | 23,110 | $38K |
| Raymond James Financial Inc. | 0.00% | New | 22,164 | $37K |
| Acadian Asset Management LLC | 0.00% | New | 22,418 | $36K |
| Commonwealth Equity Services, LLC | 0.00% | No change | 18,298 | $30K |
| State Street Corp. | 0.00% | No change | 15,765 | $26K |
| Gsa Capital Partners LLP | 0.00% | New | 13,466 | $22K |
| Renaissance Technologies | 0.00% | Reduce -90.8% | 10,543 | $17K |
| Corsair Capital Management, L.P. | 0.00% | New | 10,000 | $17K |
| Morgan Stanley | 0.00% | Reduce -73.4% | 3,411 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -34.7% | 2,804 | $5K |
| Royal Bank of Canada | 0.00% | No change | 2,440 | $4K |
| Bank of America Corp. | 0.00% | Reduce -91.4% | 1,469 | $2K |
| Mb, Levis & Associates, LLC | 0.00% | No change | 1,041 | $2K |
| Centerpoint Advisors, LLC | 0.00% | No change | 350 | $1K |
| Cwm, LLC | 0.00% | No change | 500 | $1K |
| JPMorgan Chase & Co. | 0.00% | Reduce -97.6% | 146 | $241 |
| Wells Fargo & Company | 0.00% | No change | 65 | $107 |
| Truvestments Capital LLC | 0.00% | No change | 25 | $41 |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 11 | $18 |
"% of holder's portfolio" is VYNE THERAPEUTICS INC's weight in each manager's 13F, not the share of Vyne Therapeutics Inc. the manager owns.